J&J Raises Forecast as Profit Climbs on Demand for Drugs
This article is for subscribers only.
Johnson & Johnson, the world’s second-biggest maker of health-care products, raised its full-year earnings forecast after quarterly profit climbed on the divestiture of an older drug and revenue from new medicines.
Earnings excluding one-time items will be $5.07 to $5.17 a share for 2012, helped by currency exchange rates, New Brunswick, New Jersey-based J&J said in a statement today. Last quarter, the company provided a forecast of as much as $5.15.